⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Accelera S.r.l. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Accelera S.r.l.
↗Nerviano (Milan), Italy
Accelera is a premium-tier Contract Research Organization (CRO) based in Nerviano, Italy, specializing in integrated preclinical safety assessment, toxicology, and efficacy testing. As a division of the Nerviano Medical Sciences (NMS) Group, the company provides GLP-compliant services to support pharmaceutical and biotechnology companies in advancing drug candidates from early discovery through to regulatory submission (IND/CTA).
The company leverages over 60 years of heritage at the Nerviano site, offering expertise in small molecules, biologics, and advanced modalities. Accelera is fully GLP and AAALAC accredited and focuses on de-risking development programs through robust scientific data, translational research, and regulatory consulting.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2004
Ownership:subsidiary
Status:operating
PIPELINE
Stage:Discovery
Lead Drug Stage:N/A (Service Provider)
Modalities:Small molecule, Biologics, Cell therapy, Oligonucleotides
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Nerviano Medical Sciences (NMS) Group
Key Partnerships:Nerviano Medical Sciences (NMS) Group, NerPharMa
COMPETITION
Position:Niche Player
Competitors:Charles River Laboratories, Labcorp Drug Development, Eurofins Advinus, Envigo
LEADERSHIP
Key Executives:
Silvia Guionaud - CEO
Hugues Dolgos - Chairman of the Board
LINKS
Website:accelera.org
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Accelera S.r.l.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.